Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 11/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 9/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 9/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22777840 | 0.88 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4CAMKK2OPRL1 | |
| SCHEMBL22777902 | 0.86 | PBRM1 (0.38) | PBRM1SMARCA2SMARCA4CAMKK2OPRL1 | |
| SCHEMBL22777874 | 0.85 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4CAMKK2BTK | |
| SCHEMBL22777879 | 0.85 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4CAMKK2OPRL1 | |
| SCHEMBL22777907 | 0.85 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4CAMKK2BTK | |
| SCHEMBL22777871 | 0.85 | PBRM1 (0.37) | PBRM1SMARCA2SMARCA4CAMKK2BTK | |
| SCHEMBL22777857 | 0.84 | PBRM1 (0.40) | PBRM1SMARCA2SMARCA4CAMKK2OPRL1 | |
| SCHEMBL22777912 | 0.82 | BTK (0.37) | PBRM1SMARCA2SMARCA4CAMKK2BTK | |
| SCHEMBL22790943 | 0.81 | CYP1A2 (0.49) | PBRM1SMARCA2SMARCA4 | |
| SCHEMBL25468671 | 0.80 | PTPN11 (0.41) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521438-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2020251972-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | PBRM1 5/4885SMARCA2 6/4885SMARCA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.